Gene · 4585
Papers4,232
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 4,232
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| YAP1::KMT2A fusion-positive sarcoma: An emerging soft tissue tumor entity with morphological features resembling a sclerosing epithelioid fibrosarcoma. | Indian J Pathol Microbiol | 2024 | 38975722 | PubTator, text mining | PubMed |
| Circadian disruption reduces MUC4 expression via the clock molecule BMAL1 during dry eye development. | Exp Mol Med | 2024 | 38956298 | PubTator, text mining | PubMed |
| An extensive immunohistochemical analysis of 290 ovarian adult granulosa cell tumors with 29 markers. | Virchows Arch | 2024 | 38904760 | PubTator, text mining | PubMed |
| A 35-gene mutation profile predicts the therapeutic outcome of patients with esophageal squamous cell carcinoma receiving neo-adjuvant chemoradiation. | Am J Cancer Res | 2024 | 38859831 | PubTator, text mining | PubMed |
| A novel fatty acid metabolism-related signature identifies MUC4 as a novel therapy target for esophageal squamous cell carcinoma. | Sci Rep | 2024 | 38816411 | PubTator, text mining | PubMed |
| Discovery of Pathogenic Variants Associated with Idiopathic Recurrent Pregnancy Loss Using Whole-Exome Sequencing. | Int J Mol Sci | 2024 | 38791485 | PubTator, text mining | PubMed |
| Surface plasmon resonance microscopy identifies glycan heterogeneity in pancreatic cancer cells that influences mucin-4 binding interactions. | PLoS One | 2024 | 38776309 | PubTator, text mining | PubMed |
| Single-cell transcriptomics reveals the aggressive landscape of high-grade serous carcinoma and therapeutic targets in tumor microenvironment. | Cancer Lett | 2024 | 38714290 | PubTator, text mining | PubMed |
| Clinical Significance of MUC4 and Associated Proteins in Pancreatic and Periampullary Cancers. | Pancreas | 2024 | 38696350 | PubTator, text mining | PubMed |
Case report: Mutation evolution in a patient with TdT positive high grade B cell lymphoma with MYC and BCL2 rearrangements following the treatment of concurrent follicular lymphoma and diffuse large B-cell lymphoma. | Discov Oncol | 2024 | 38662249 | PubTator, text mining | PubMed |
| Establishment of a cholangiocarcinoma risk evaluation model based on mucin expression levels. | World J Gastrointest Oncol | 2024 | 38660669 | PubTator, text mining | PubMed |
| [Clinicopathological and molecular genetic features of Crohn's disease]. | Zhonghua Bing Li Xue Za Zhi | 2024 | 38556818 | PubTator, text mining | PubMed |
| Sclerosing epithelioid fibrosarcoma of the jaw: a case report and literature review. | Oral Surg Oral Med Oral Pathol Oral Radiol | 2024 | 38553308 | PubTator, text mining | PubMed |
| Exploring the Role of Non-synonymous and Deleterious Variants Identified in Colorectal Cancer: A Multi-dimensional Computational Scrutiny of Exomes. | Curr Genomics | 2024 | 38544823 | PubTator, text mining | PubMed |
| Characterizing and forecasting neoantigens-resulting from MUC mutations in COAD. | J Transl Med | 2024 | 38539235 | PubTator, text mining | PubMed |
| Mutational profile evaluates metastatic capacity of Chinese colorectal cancer patients, revealed by whole-exome sequencing. | Genomics | 2024 | 38492821 | PubTator, text mining | PubMed |
| Primary sclerosing epitheloid fibrosarcoma of the kidney: First case reported in Mexico. | Urol Case Rep | 2024 | 38463612 | PubTator, text mining | PubMed |
| Intra-Abdominal Epithelioid Neoplasm With EWSR1::CREB Fusions Involving the Kidney: A Clinicopathologic and Molecular Characterization With an Emphasis on Differential Diagnosis. | Mod Pathol | 2024 | 38460673 | PubTator, text mining | PubMed |
| Adjustment of scRNA-seq data to improve cell-type decomposition of spatial transcriptomics. | Brief Bioinform | 2024 | 38426323 | PubTator, text mining | PubMed |
| Diatomite-Based, Flexible SERS Immunosensor Platform for Rapid, Specific, and Sensitive Detection of Circulating Cancer-Specific Protein Biomarkers in Serum Using Raman Probes. | ACS Appl Bio Mater | 2024 | 38414330 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4585/papers?page=11